At @ weeks , greater improvements in adjusted mean change from baseline HbA@c ( difference vs placebo -LSB- @ % CI -RSB- , -@ % -LSB- -@ % , -@ % -RSB- , -LSB- -@ ( -@ , -@ ) mmol/mol -RSB- , P < @ ) , FPG ( -@ -LSB- -@ , -@ -RSB- mmol/L , P = @ ) , PPG AUC@-@ ( -@ -LSB- -@ , -@ -RSB- mmol min/L , P < @ ) , C-peptide AUC@-@ ( @ -LSB- @ , @ -RSB- nmol min/L , P = @ ) , insulinogenic index ( @ % -LSB- @ % , @ % -RSB- , P = @ ) , and greater suppression of glucagon secretion ( glucagon AUC@-@ , -@ -LSB- -@ , -@ -RSB- pmol min/L , P = @ ) were observed with saxagliptin versus placebo .